Sera Prognostics, Inc. (SERA) Stock Analysis & Investment Frameworks
Sera Prognostics, Inc. (SERA) stock analysis on Invetso. Review Sera Prognostics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Sera Prognostics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Sera Prognostics, Inc. Key Financial Metrics
- Market Cap: $78.12M
- Revenue: $81000.00
- ROE: -46.71%
- ROIC: -59.79%
- Dividend Yield: N/A
About Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Sera Prognostics, Inc. Investment Frameworks
Invetso analyzes Sera Prognostics, Inc. (SERA) across the following frameworks:
- Sera Prognostics, Inc. 10Y Growth Potential
- Sera Prognostics, Inc. Scenario Analysis
- Sera Prognostics, Inc. Risks & Opportunities
- Sera Prognostics, Inc. Economic Moat
- Sera Prognostics, Inc. Business Model
- Sera Prognostics, Inc. Management
- Sera Prognostics, Inc. SWOT Analysis
- Sera Prognostics, Inc. Porter's 5 Forces
- Sera Prognostics, Inc. PESTLE Analysis
- Sera Prognostics, Inc. ESG Analysis